Insmed (INSM) Long-Term Investments (2021 - 2022)

Insmed's (INSM) quarterly Long-Term Investments came in at $9.8 million in Q2 2022, down 66.96% quarter-over-quarter from $29.6 million in Q1 2022.

Insmed (INSM) Long-Term Investments (2021 - 2022) Analysis & Trends

Insmed's Long-Term Investments history runs 2 years deep, the most recent figure standing at $9.8 million for Q2 2022.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $9.8 million in Q2 2022; TTM through Jun 2022 was $9.8 million, a N/A change from a year earlier, with the FY2021 full-year figure at $50.0 million, changed N/A from the prior year.
Long-Term Investments fell to $9.8 million in Q2 2022 per INSM's latest filing, from $29.6 million in the prior quarter.
Across five years, Long-Term Investments topped out at $50.0 million in Q4 2021 and bottomed at $9.8 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Insmed	23.26 Bn	22.03 Bn	258.54 Mn	-

Download Data